

as unacceptable as those situations encountered by service users who feel that they have been 'preached at' by their atheist psychiatrist.

Declaration of interest

C.C.H.C. is in receipt of a grant from the Guild of Health and is an Anglican priest. He is currently Chair of the Spirituality and Psychiatry Special Interest Group (SPSIG) at the Royal College of Psychiatrists. The views expressed in this article are his own.

- 1 Cook CCH. *Recommendations for Psychiatrists on Spirituality and Religion* (Position Statement PS03/2011). Royal College of Psychiatrists, 2011.

Christopher C. H. Cook, University of Durham, Durham, UK.
Email: c.c.h.cook@durham.ac.uk

doi: 10.1192/bjp.199.6.517a

Author's reply: Drs Haley, Davies and Sarkar raise issues concerning religion, spirituality and clinical practice beyond the narrow question of prayer.

I am grateful to Dr Haley for setting a broader sociopolitical context. I concur with the points he makes, which underline the fact that this debate is concerned with tangible realities, not abstract differences of belief.

Dr Davies uses three rhetorical devices that have been recurrently utilised by 'the other side' in the broad debate. First, he argues on the basis of the fundamental philosophical fallacy of a category error. Religious faith, ethical codes, cognitive therapy and, for that matter, science may all in some way involve belief, but they are not comparable, competing belief systems. They are fundamentally dissimilar. Religious faith is concerned with transcendent, immutable truths that are outside of the realm of reason or evidence. This does not invalidate faith, but it is dissimilar to other types of belief.

Second, Davies assumes that my position is primarily determined by my atheism. However, many professionals with a strong religious faith agree with me,¹ because the debate is concerned with professional boundaries, not personal convictions. In the debate with Professor Cook, I mention my participation in a meeting on 'intolerant secularism' at the Royal College of Psychiatrists in October 2010.² Professor Andrew Sims, Lord Carey and Andrea Minichiello Williams had hoped to persuade the College's Spirituality and Psychiatry Special Interest Group (SPSIG) to campaign for the right of professionals to express disapproval of homosexual lifestyles in their work, and for a distinctively Christian orientation to public and professional life in general. The SPSIG showed no inclination to support this, which does not suggest that it is only atheists who are troubled by the implications of some of the realities of integrating religion into clinical practice.

Finally, Davies leaps to the suggestion that my stance is associated with an attachment to biological determinism and overattachment to a particular theoretical stance within psychiatry. There is no logical link. Personally, I reject biological determinism and theoretical fanaticism because, in my opinion, they are based on bad science. I cannot see how religious belief (or non-belief) is relevant.

Dr Sarkar has published extensively on boundary violations, and I am pleased that he agrees with me that the issues concerning prayer and religious practice are not intrinsically different from other boundary issues.

In calling for the College to commission a working group, he echoes a similar suggestion published in *The Psychiatrist* in

October 2010.³ This was addressed to the immediate past-President of the College, who did not respond. Instead, a position paper, written by Professor Cook on behalf of the SPSIG, has quietly passed through the College committee machinery, and is now Royal College of Psychiatrists policy.⁴

On the one hand, the College's position paper⁴ emphasises that proselytisation is unacceptable, which is welcome. On the other hand, none of the key boundary issues is addressed, a scientifically controversial position has been adopted with regard to evidence, and the official position of British organised psychiatry is that 'an understanding of religion and spirituality and their relationship to the diagnosis, aetiology and treatment of psychiatric disorders should be considered as essential components of both psychiatric training and continuing professional development' (p. 8). This is already having an impact on services. For example, Mersey Care NHS Trust is holding a conference to promote integration of spirituality into psychiatric care⁵ on the basis that this is a College recommendation.

This debate has teeth, and we are already set on a course that I find extremely worrying. Those who agree with me on the importance of boundaries should make their voices heard now, as we may soon find ourselves in a very difficult place.

Declaration of interest

R.P. is an atheist.

- 1 Poole R, Higgs R, Strong G, Kennedy G, Ruben S, Barnes R, et al. Religion, psychiatry and professional boundaries. *Psychiatr Bull* 2008; **32**: 356–7.
- 2 Poole R. Secularism as a professional boundary in psychiatry. Spirituality and Psychiatry Special Interest Group Newsletter, no. 30, December 2010. (<http://www.rcpsych.ac.uk/members/specialinterestgroups/spirituality/publicationsarchive/newsletter30.aspx>).
- 3 Poole R, Higgs R. Psychiatry, religion and spirituality: a way forward. *Psychiatrist* 2010; **34**: 452–3.
- 4 Cook CCH. *Recommendations for Psychiatrists on Spirituality and Religion* (Position Statement PS03/2011). Royal College of Psychiatrists, 2011.
- 5 Mersey Care NHS Trust. Living in Hope: Spirituality and Practice in Mental Health Care. Mersey Care NHS Trust, 2011 (http://www.mersecare.nhs.uk/Library/Living_in_Hope/Living%20in%20Hope%20Flyer.pdf).

Rob Poole, Glyndwr University, Wrexham, UK. Email: rob.poole@wales.nhs.uk

doi: 10.1192/bjp.199.6.518

Clozapine and bladder control

Harrison-Woolrych *et al*¹ present an interesting exploration of the association between nocturnal enuresis and clozapine (and other atypical antipsychotic) use. They report a significantly higher rate of nocturnal enuresis with clozapine use than with the other antipsychotics assessed in the study. This suggests a possible mechanism specific to clozapine in causation of this event.

Clozapine has been shown to adversely influence bladder control.^{2–4} Various putative mechanisms to explain this observation include retention overflow consequent to inhibition of detrusor contraction due to anticholinergic action, reduced sphincter tone due to anti-adrenergic activity,⁵ sedation and lowering of the seizure threshold,⁶ drug-induced diabetes mellitus resulting in polyuria⁶ and drug-induced diabetes insipidus.⁷ Preclinical studies have demonstrated clozapine's effects on urodynamics, with a centrally regulated reduction in activity of the external urethral sphincter.⁸

Bladder deregulation among patients with schizophrenia was described by Kraepelin, who postulated it to be an accompaniment of the ongoing 'dementia' process, as evident by the

neuropsychological correlates of this process.⁹ More recent works^{10,11} have also established bladder dysfunction among patients with schizophrenia. The cause was reported to be detrusor hyperreflexia in both studies based on the findings of urodynamic studies.

Similarly, high rates of bladder dysfunction have been reported among patients with schizophrenia being treated with clozapine.^{2–4} However, the reports implicating clozapine in causation of bladder dysregulation have been criticised for concomitant use of other antipsychotics in these individuals.⁴ Likewise, the dose of clozapine reported in these cases has been on the higher side.

In this context, it would be interesting to make a mention of a paper reporting a possible curative role of clozapine in neurogenic bladder.¹² This effect of clozapine was observed in a patient with schizophrenia. However, resolution of urinary incontinence in this case was found to be unrelated to the clinical response for schizophrenia. A high Naranjo algorithm score (>9), single-photon emission computed tomography and urodynamic findings lend support to the arguments put forward by the authors. Another interesting observation in the case was a therapeutic window phenomenon. Urinary incontinence responded to a dose range of 250–300 mg/day. No response was observed at a lower dose and incontinence reappeared at doses exceeding 300 mg/day. The authors postulated a possible central mechanism for this observation. Reversal of the facilitatory role of the 5-HT₇ heteroreceptor on acetylcholine release by clozapine could underlie its possible role in urge incontinence.¹³

There are no further reports or studies on the possible role of clozapine in correction of neurogenic bladder, nor has the dose–response effect been studied. It would be interesting to analyse the data by Harrison-Woolrych *et al*¹ for the effect of dose of clozapine and to see whether there is any pattern with regard to change in nocturnal enuresis.

- 1 Harrison-Woolrych M, Skegg K, Ashton J, Herbison P, Skegg DCG. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. *Br J Psychiatry* 2011; **199**: 140–4.
- 2 Jeong SH, Kim JH, Ahn YM, Lee KY, Kim SW, Jung DC, et al. A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. *J Clin Psychopharmacol* 2008; **28**: 618–24.
- 3 Lin CC, Bai YM, Chen JY, Lin CY, Lan TH. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. *Acta Psychiatr Scand* 1999; **100**: 158–61.
- 4 Clark N. Conventional antipsychotic and clozapine-induced urinary incontinence. *J Coll Psychiatr Neurol Pharmacist* 2003; **2**: 1–8.
- 5 Warner JP, Harvey CA, Barnes TR. Clozapine and urinary incontinence. *Int Clin Psychopharmacol* 1994; **9**: 207–9.
- 6 Kho KH, Nielsen O. Clozapine-induced nocturnal enuresis: diagnostic and treatment issues. *Psychiatr Bull* 2001; **25**: 232–3.
- 7 Bendz H, Aurell M. Drug-induced diabetes insipidus. *Drug Saf* 1999; **21**: 449–56.
- 8 Vera PL, Nadelhaft I. Clozapine inhibits micturition parameters and the external urethral sphincter during cystometry in anaesthetized rats. *Brain Res* 2001; **901**: 219–29.
- 9 Kraepelin E. *Dementia Praecox and Paraphrenia* (trans RM Barclay): 77–83. Robert E. Krieger Press, 1971.
- 10 Bonney WW, Gupta S, Hunter DR, Arndt S. Bladder dysfunction in schizophrenia. *Schizophr Res* 1997; **25**: 243–9.
- 11 Gupta S, Bonney WW, Sethi PS, Hunter DR. Preliminary report: detrusor hyperreflexia in schizophrenia. *NeuroUrol Urodyn* 1995; **14**: 371–8.
- 12 Kumar A, Chadda RK, Kumar N, Balan S, Srinivasan SP. Clozapine for the treatment of neurogenic bladder. *NeuroUrol Urodyn* 2007; **26**: 537–9.
- 13 Saifullah AS, Tomioka K. 5-HT(7)-like receptors mediate serotonergic modulation of photo-responsiveness of the medulla bilateral neurons in the cricket *Gryllus bimaculatus*. *Zoolog Sci* 2003; **20**: 303–9.

Yatan Balhara, Department of Psychiatry, Lady Hardinge Medical College and Smt. SK Hospital, New Delhi, India 110001. Email: ypsbalhara@gmail.com

doi: 10.1192/bjp.199.6.518a